Marksans Pharma gets 2 USFDA observations for Goa facility
Advertisement
Mumbai: Marksans Pharma has announced that the United State Food and Drug Administration (USFDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection. The inspection closed with two observations.
The inspection was conducted at its Goa, Verna manufacturing facility from 31st July, 2023 to 4th August, 2023.
The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans' marketed products.
"We will submit corrective and preventive action plan (CAPA) to the US FDA in the stipulated time frame," the company stated in a BSE filing.
Read also: Marksans Pharma concludes acquisition of Tevapharm India's Goa manufacturing site
Marksans Pharma Ltd headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The company is marketing these products globally.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.